GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » EV-to-EBITDA

HAEMATO AG (XTER:HAEK) EV-to-EBITDA : 6.35 (As of May. 13, 2024)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HAEMATO AG's enterprise value is €88.6 Mil. HAEMATO AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €14.0 Mil. Therefore, HAEMATO AG's EV-to-EBITDA for today is 6.35.

The historical rank and industry rank for HAEMATO AG's EV-to-EBITDA or its related term are showing as below:

XTER:HAEK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -36.96   Med: 8.61   Max: 44.77
Current: 3.97

During the past 13 years, the highest EV-to-EBITDA of HAEMATO AG was 44.77. The lowest was -36.96. And the median was 8.61.

XTER:HAEK's EV-to-EBITDA is ranked better than
91.76% of 704 companies
in the Drug Manufacturers industry
Industry Median: 14.705 vs XTER:HAEK: 3.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), HAEMATO AG's stock price is €21.40. HAEMATO AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.842. Therefore, HAEMATO AG's PE Ratio for today is 11.62.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


HAEMATO AG EV-to-EBITDA Historical Data

The historical data trend for HAEMATO AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG EV-to-EBITDA Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.58 42.14 -47.11 8.02 4.93

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8.02 - 4.93 -

Competitive Comparison of HAEMATO AG's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's EV-to-EBITDA falls into.



HAEMATO AG EV-to-EBITDA Calculation

HAEMATO AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=88.594/13.959
=6.35

HAEMATO AG's current Enterprise Value is €88.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HAEMATO AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €14.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HAEMATO AG  (XTER:HAEK) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

HAEMATO AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21.40/1.842
=11.62

HAEMATO AG's share price for today is €21.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HAEMATO AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.842.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


HAEMATO AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines